Immunovia AB Statistics

Total Valuation

Immunovia AB has a market cap or net worth of SEK 136.36 million. The enterprise value is 98.80 million.

Market Cap	136.36M
Enterprise Value	98.80M

Important Dates

The next estimated earnings date is Thursday, August 21, 2025.

Earnings Date	Aug 21, 2025
Ex-Dividend Date	n/a

Share Statistics

Immunovia AB has 306.08 million shares outstanding. The number of shares has increased by 195.20% in one year.

Current Share Class	306.08M
Shares Outstanding	306.08M
Shares Change (YoY)	+195.20%
Shares Change (QoQ)	+42.25%
Owned by Insiders (%)	6.89%
Owned by Institutions (%)	15.18%
Float	284.64M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	149.19
PB Ratio	4.66
P/TBV Ratio	4.95
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-0.75
EV / Sales	108.10
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.84, with a Debt / Equity ratio of 0.00.

Current Ratio	2.84
Quick Ratio	2.84
Debt / Equity	0.00
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-2.57

Financial Efficiency

Return on equity (ROE) is -360.19% and return on invested capital (ROIC) is -159.63%.

Return on Equity (ROE)	-360.19%
Return on Assets (ROA)	-113.82%
Return on Invested Capital (ROIC)	-159.63%
Return on Capital Employed (ROCE)	-357.28%
Revenue Per Employee	101,556
Profits Per Employee	-14.60M
Employee Count	9
Asset Turnover	0.02
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -72.84% in the last 52 weeks. The beta is 2.81, so Immunovia AB's price volatility has been higher than the market average.

Beta (5Y)	2.81
52-Week Price Change	-72.84%
50-Day Moving Average	0.34
200-Day Moving Average	0.52
Relative Strength Index (RSI)	60.47
Average Volume (20 Days)	2,838,666

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Immunovia AB had revenue of SEK 914,000 and -131.39 million in losses. Loss per share was -1.00.

Revenue	914,000
Gross Profit	914,000
Operating Income	-104.54M
Pretax Income	-131.39M
Net Income	-131.39M
EBITDA	-92.89M
EBIT	-104.54M
Loss Per Share	-1.00

Full Income Statement

Balance Sheet

The company has 37.67 million in cash and 110,000 in debt, giving a net cash position of 37.56 million or 0.12 per share.

Cash & Cash Equivalents	37.67M
Total Debt	110,000
Net Cash	37.56M
Net Cash Per Share	0.12
Equity (Book Value)	29.26M
Book Value Per Share	0.11
Working Capital	26.77M

Full Balance Sheet

Cash Flow

Operating Cash Flow	-96.70M
Capital Expenditures	n/a
Free Cash Flow	n/a
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	100.00%
Operating Margin	-11,437.31%
Pretax Margin	-14,374.95%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Immunovia AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-195.20%
Shareholder Yield	n/a
Earnings Yield	-96.35%
FCF Yield	n/a

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Immunovia AB has an Altman Z-Score of -41.38 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-41.38
Piotroski F-Score	4